Glaukos Corp. Cash Flow Statement
GKOS / Health Care|13 years of annual SEC 10-K data (FY2013-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 13 fiscal years. All figures from audited SEC 10-K filings.
Glaukos Corp. used $15M in operating cash flow and negative free cash flow of $22M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$187.7M | -$146.4M | -$134.7M | -$99.2M | -$49.6M | -$120.3M | $15.4M | -$13.0M | -$92.0K | $4.5M | -$37.2M | -$12.1M | -$12.6M |
| Depreciation & Amortization | $38.1M | $35.6M | $33.7M | $31.6M | $29.7M | $29.4M | $6.3M | $6.3M | $5.5M | $4.7M | $4.3M | $4.2M | $1.2M |
| Operating Cash Flow | -$14.8M | -$61.3M | -$57.8M | -$33.1M | $24.7M | -$23.0M | -$369.0K | $18.9M | $26.1M | $12.3M | -$2.2M | -$7.1M | -$13.3M |
| Capital Expenditures | $7.7M | $6.3M | $20.2M | $30.3M | $47.8M | $6.9M | $4.7M | $10.3M | $6.3M | $6.3M | $877.0K | $868.0K | $852.0K |
| Free Cash Flow | -$22.5M | -$67.6M | -$78.0M | -$63.3M | -$23.1M | -$29.9M | -$5.1M | $8.5M | $19.8M | $6.0M | -$3.1M | -$8.0M | -$14.2M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | $132.0K |
| FCF Margin | -4.4% | -17.6% | -24.8% | -22.4% | -7.8% | -13.3% | -2.1% | 4.7% | 12.4% | 5.3% | -4.3% | -17.5% | - |